| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT00427349 | Gastrointestinal Carcinoid Tumor|Islet Cell Tumor|Neoplastic Syndrome | Drug: AMG 706|Drug: octreotide | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) | Phase 2 | 2008-09-01 | 2016-07-12 |
| NCT01836549 | Anaplastic Astrocytoma|Anaplastic Ependymoma|Astrocytoma, Grade II|Ependymoma|Giant Cell Glioblastoma|Glioblastoma|Gliosarcoma|Oligodendroglioma|Brainstem Tumors | Drug: imetelstat sodium | Pediatric Brain Tumor Consortium|National Cancer Institute (NCI) | Phase 2 | 2013-03-01 | 2016-04-08 |
| NCT00360867 | Solid Tumors | Drug: AMG 706 | Amgen | Phase 2 | 2005-12-01 | 2015-09-24 |
| NCT01731951 | Primary Myelofibrosis|Secondary Myelofibrosis|Myeloid Malignancies | Drug: Imetelstat | Janssen Research & Development, LLC | Phase 2 | 2012-10-01 | 2016-12-02 |
| NCT01242930 | Multiple Myeloma | Drug: Imetelstat (7.5 mg/kg)|Drug: lenalidomide standard of care|Drug: Imetelstat (9.4 mg/kg) | Geron Corporation | Phase 2 | 2010-11-01 | 2016-04-13 |
| NCT00574951 | Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer | Drug: motesanib diphosphate | Gynecologic Oncology Group|National Cancer Institute (NCI) | Phase 2 | 2007-12-01 | 2015-05-29 |
| NCT02011126 | Childhood Hepatoblastoma|Previously Treated Childhood Rhabdomyosarcoma|Recurrent Childhood Liver Cancer|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Neuroblastoma|Recurrent Osteosarcoma | Drug: imetelstat sodium|Other: laboratory biomarker analysis | Children's Oncology Group|National Cancer Institute (NCI) | Phase 2 | 2014-06-01 | 2017-02-08 |
| NCT01386866 | Advanced Solid Tumors | Drug: AMG 706 | Amgen | Phase 1 | 2009-05-01 | 2011-07-14 |
| NCT02426086 | Primary Myelofibrosis | Drug: Imetelstat 9.4 milligram/kilogram (mg/kg)|Drug: Imetelstat 4.7 mg/kg | Janssen Research & Development, LLC | Phase 2 | 2015-06-01 | 2016-10-31 |
| NCT01916187 | Neuroblastoma | Drug: Imetelstat | NCIC Clinical Trials Group|Geron Corporation|Canadian Cancer Trials Group | Phase 1 | 2013-07-01 | 2014-02-07 |
| NCT01137968 | Non-small Cell Lung Cancer | Drug: imetelstat|Drug: Bevacizumab | Geron Corporation | Phase 2 | 2010-05-01 | 2015-12-22 |
| NCT02598661 | Myelodysplastic Syndromes | Drug: Imetelstat|Drug: Placebo | Janssen Research & Development, LLC | Phase 3 | 2015-11-01 | 2017-01-13 |
| NCT00254267 | Advanced Gastrointestinal Stromal Tumor | Drug: AMG 706 | Amgen|Takeda Bio Development Center, Ltd | Phase 2 | 2005-11-01 | 2014-02-26 |
| NCT02629848 | Carcinoma, Non-Small-Cell Lung | Drug: Motesanib|Drug: Placebo|Drug: Paclitaxel|Drug: Carboplatin | Takeda | Phase 3 | 2012-07-01 | 2015-12-10 |
| NCT00356681 | Breast Neoplasms|Breast Tumors|Breast Cancer|Locally Recurrent and Metastatic Breast Cancer | Drug: AMG 706 placebo|Drug: Bevacizumab|Drug: AMG 706|Drug: Paclitaxel | Amgen | Phase 2 | 2006-12-01 | 2015-09-24 |
| NCT00094835 | Lung Cancer|Non-Small Cell Lung Cancer | Biological: Panitumumab|Drug: Motesanib diphosphate|Drug: Paclitaxel|Drug: Carboplatin | Amgen | Phase 1|Phase 2 | 2005-01-01 | 2016-02-26 |
| NCT00369070 | Advanced Non-squamous NSCLC | Biological: Bevacizumab|Drug: AMG 706|Drug: Paclitaxel|Drug: Carboplatin | Amgen | Phase 2 | 2007-01-01 | 2016-06-09 |
| NCT00124189 | Chronic Lymphoproliferative Diseases | Drug: GRN163L | Geron Corporation | Phase 1 | 2005-07-01 | 2015-12-22 |
| NCT00093873 | Tumors | Drug: Anti-angiogenesis|Drug: AMG 706 | Amgen | Phase 1 | 2003-07-01 | 2013-05-13 |
| NCT01256762 | Locally Recurrent or Metastatic Breast Cancer | Drug: Imetelstat sodium|Drug: Bevacizumab|Drug: Paclitaxel | Geron Corporation | Phase 2 | 2010-11-01 | 2015-12-22 |
